TAP2 and lung cancer: TAP deficiencies have been observed in a wide variety of human cancers, including cervical carcinoma [81], head and neck carcinoma [82], melanoma, gastric cancer [83,84], and lung cancer, with up to 70% of NSCLC expressing low levels of TAP1 and/or TAP2.